John R. Haserick, PhD
VP, Platform Development
Dr. John Haserick is the VP of platform development at Innovac Therapeutics. Dr. Haserick earned his MS in Cell Biology from the University of Connecticut while transitioning into an R&D role at BioPhysics Assay Laboratory (BioPAL) where he gained experience with nanoparticle-based product, synthesis, analytics, and in vitro testing. He pursued his PhD in Biochemistry from Boston University School of Medicine. There, he utilized mass spectrometry to detail the glycoproteomes and elucidate the novel glycan structures from human pathogens. At Agenus, he played a critical role in the development of a personalized anti-cancer vaccine. Dr. Haserick improved the formulation, manufacturability, analytics, and streamlined release tests of the drug products. His strong background in cell biology, biochemistry, glycobiology, and cutting-edge analytics provides a unique perspective and deep understanding into the biology. With more than 19 years of experience in academia, industrial R&D, and bio-pharmaceutical drug development settings, Dr. Haserick’s innovative solutions and streamlined approach rapidly advanced the chemistry, manufacturing, and analytics of Innovac’s therapeutic pipeline.